Clinical Trial Update: Monoclonal Antibody Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

This clinical trial update describes a Phase 2 study of a monoclonal antibody therapy for patients with relapsed or refractory Non-Hodgkin lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• Monoclonal antibody therapy (unspecified)

Snippet

Sponsor: PDL BioPharma, Inc. | Conditions: Lymphoma | Phase 2 | Status: UNKNOWN